News

Reported sales of $510 million in the fourth quarter ended December, 2008 declined by 4% compared to 2007. Excluding the impact of currency, sales in the fourth quarter

The new agreement addresses the five existing technologies and two applications in development of the Artelon spacer portfolio designed to treat arthritis within small bone and joints. Small

According to the company, the new connector system, which includes the Durata defibrillation lead with the SJ4 connector and the Promote CRT-D with the SJ4 connector, is expected

The open-label, dose-escalating pivotal trial has been designed to measure durable local complete response at the tumor site. Celsion expects to enroll approximately 100 patients across the US

The study, Revive-diabetes, is a multicenter, randomized, double-blind, placebo-controlled trial and will evaluate the safety and efficacy of avanafil in the treatment of erectile dysfunction (ED) in men

The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer. Fujirebio also grants

Alton Boynton, Northwest Biotherapeutics’s CEO, said: “We are very pleased to have completed another interim financing despite severely adverse general market conditions. We look forward to continuing the

ELISA is provided with all reagents required including a pre-coated microplate eliminating the need for an overnight incubation found with other commercially available kits. Results are achieved in

Total revenues in 2008 were $4.1 billion, an increase of 29% from $3.2 billion in 2007. The company has reported net income of $207 million for the fourth